<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700515</url>
  </required_header>
  <id_info>
    <org_study_id>EPO-EXO</org_study_id>
    <nct_id>NCT03700515</nct_id>
  </id_info>
  <brief_title>Exosome Proteomics to Detect EPO</brief_title>
  <official_title>Exosome Proteomics to Detect Eyrthropoietin (EPO) Use in Athletes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morten Hostrup, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tasmania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of exosomes in cell signalling has only recently been appreciated and is a hugely
      exciting and rapidly growing area, and combined with LC-MS/MS proteomics, can overcome
      traditional barriers to proteomics in doping applications. To our knowledge, no research has
      yet been undertaken to explore whether the highly promising combination of exosome proteomics
      has utility for rhEPO detection. The applications are extensive; the diagnostic value of
      differentially regulated proteins could be further validated against the existing IEF EPO
      WADA accredited tests using samples collected during this study, used to study altitude
      hypoxia versus exogenous EPO administration (WADA current targeted research 2017),
      investigated as a platform approach to ESA and HIF agents more generally, as well as
      facilitate development of direct ELISA high throughput tests.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">October 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood proteome enrichment pathway analysis in GO annotation</measure>
    <time_frame>At baseline and after week 3 of treatment</time_frame>
    <description>Change in enrichment (measured in blood and assessed using GO annotation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood markers of iron</measure>
    <time_frame>At baseline and after week 3 of treatment</time_frame>
    <description>Change in blood markers of iron homeostasis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erythropoetin infusion (9 IU/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPO II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erythropoetin infusion (20 IU/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Subjects receive weekly infusions of EPO</description>
    <arm_group_label>EPO</arm_group_label>
    <arm_group_label>EPO II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects receive weekly infusions of saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VO2max of at least 55+/-2 for men and 50+/-2 for women

          -  BMI between 18 and 27

          -  Resting hematocrit of less than 46%

        Exclusion Criteria:

          -  Chronic disease deemed by the medical doctor to affect the outcome

          -  Competitive athlete subject to doping control

          -  Use of other prescription medicine deemed by the medical doctor to interact with the
             study drug

          -  Allergy or otherwise unacceptable side effects toward the study drug

          -  Smoker

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>August Krogh Building</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Hostrup, PhD</last_name>
      <phone>+4524474785</phone>
      <email>mhostrup@nexs.ku.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hostrup, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>EPO</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

